Bioequivalence evaluation of two dosage forms of olanzapine 10 mg formulations in healthy volunteers

被引:0
作者
Canovas, Mercedes [1 ]
Torres, Ferran [2 ]
Domenech, Gema [2 ]
Cebrecos, Jesus [3 ]
Pelagio, Pilar [3 ]
Manriquez, Marcela [4 ]
Martinez, Gemma [1 ]
Arcabell, Marta [1 ]
Cabre, Francesc [1 ]
机构
[1] Labs Lesvi SL, Invent Farma Grp, Barcelona 08970, Spain
[2] Univ Autonoma Barcelona, Lab Biostat & Epidemiol, E-08193 Barcelona, Spain
[3] Lab Anal Dr Echevarne, Barcelona, Spain
[4] Hosp Clin Barcelona, Clin Pharmacol Unit UASP, Barcelona, Spain
来源
ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH | 2011年 / 61卷 / 02期
关键词
Atypical antipsychotic; Bioequivalence; CAS; 132539-06-1; Healthy volunteers; Olanzapine; tablet; Pharmacokinetics; ANTIPSYCHOTICS;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Two bioequivalence studies were carried Out in healthy volunteers in order to compare the rate and extent of absorption of two dosage forms (film-coated tablet and orodispersible tablet) of oral olanzapine (CAS 132539-06-1) 10 mg test formulations and the respective brand formulations as reference. Twenty and twenty-six subjects were administered olanzapine film-coated tablet or orodispersible tablet of test and reference formulations in an open-label, randomised, fasting, two-period, two-sequence, crossover study. Blood samples were taken before and within 240 h after drug administration. Plasma concentrations were determined by LC/MS/MS. Log-transformed AUC and C, values were tested for bioequivalence based on the ratios of the geometric means (test/reference). t(max) was analysed nonparametrically. The 90% confidence intervals of the geometric mean values for the test/reference ratios for AUC(0-t) and C(max) were within the bioequivalence acceptance range of 80-125%. It may be therefore concluded that the test formulations of olanzapine 10 mg film-coated tablet and orodispersible tablet are bioequivalent to the reference products and can be prescribed interchangeably.
引用
收藏
页码:75 / 79
页数:5
相关论文
共 13 条
[1]  
[Anonymous], 1996, INT C HARM, pE6
[2]   Atypical antipsychotics: Part II - Adverse effects, drug interactions, and costs [J].
Brown, CS ;
Markowitz, JS ;
Moore, TR ;
Parker, NG .
ANNALS OF PHARMACOTHERAPY, 1999, 33 (02) :210-217
[3]  
CHOW SC, 2000, DESIGN ANAL BIOAVAIL, P125
[4]  
CPMP, 2010, GUID INV BIOEQ
[5]  
*EUR MED AG, ZYPR VEL SUMM PROD C
[6]  
*EUR MED AG, ZYPR SUMM PROD CHAR
[7]  
*FOOD DRUG ADM, ZYPR LAB INF
[8]   New antipsychotics: The present status [J].
Gerlach, J ;
Peacock, L .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 :39-48
[9]  
HAUSCHKE D, 1990, INT J CLIN PHARM TH, V28, P72
[10]   A COMPARISON OF THE 2 ONE-SIDED TESTS PROCEDURE AND THE POWER APPROACH FOR ASSESSING THE EQUIVALENCE OF AVERAGE BIOAVAILABILITY [J].
SCHUIRMANN, DJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1987, 15 (06) :657-680